Innovation

Solutions: Hidden Treatment

An implantable device could help patients at risk of HIV exposure get reliable, preventative medication


By Christine Hall | April 05, 2017

Remembering to take medication at the same time every day is what makes medication work. But life often gets in the way. You sleep an extra hour. You’re supposed to take your meds after a meal but you eat late, which throws off your schedule. Or, you run out of your medication and can’t get a refill.

Alessandro Grattoni, Ph.D., nanomedicine department chair at Houston Methodist Research Institute, understands the plight of patients who need to take medication consistently to control their diseases. That’s why he has worked on implantable nanochannel membranes for a decade.

Grattoni joined Houston Methodist in 2010. He was introduced to Roberto Arduino, M.D., professor of infectious disease at McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth), who is actively involved with HIV research and prevention. In 2014, the World Health Organization estimated nearly 37 million people were living with HIV/AIDS. Grattoni and Arduino started discussing possible applications of the implantable, nanofluidic drug delivery system for use in preventing HIV.

Grattoni began testing a refillable implant that would be placed under the skin—typically on the inside of the upper arm—to release medications to people at risk of HIV exposure.

Many high-risk patients already take Truvada, a combination therapy of tenofovir disoproxil fumarate and emtricitabine, to help prevent HIV-1 infection, Grattoni said. Truvada is estimated to be up to 95 percent effective in preventing HIV when taken consistently, according to a study by the Centers for Disease Control and Prevention. But the same study found the drug was only 44 percent effective among test subjects because people kept forgetting to take it, Grattoni said.

“For patients, it is easy to forget, but in the context of HIV, forgetting is really dangerous,” he said. “The implantable device stays under your skin, so it would not give you the chance to miss the medication.”

Grattoni’s implantable device works by delivering medication through silicon membranes microfabricated with the same leading-edge technologies used to produce computer chips.

The nanochannels that regulate the drug release from the implant are very small—20,000 times smaller than a human hair.

Because patients taking this type of medication typically must return to the doctor every six months for a checkup, Grattoni is working on an implant that can be refilled transcutaneously in the doctor’s office every six months or even once a year. Right now, the device can deliver HIV pre-exposure prophylaxis, or PrEP, medication for up to 70 days.

Grattoni was recently awarded a $4 million grant from the National Institute of Allergy and Infectious Diseases to increase the drug delivery time frame for HIV PrEP. If successful, the research will move to the next phase, patient clinical trials.

One of the biggest challenges is assuring drug stability throughout that six-month to one-year window, particularly since the drugs will be kept at body temperature and be surrounded by biological fluids. Pharmaceutical company Gilead is supporting the study and partnering to address drug formulation needs, Grattoni said.

Already, the device can remain in the body for a few years, he added, though he would like it to last as long as five or six years before it needs to be replaced.

Houston Methodist is leading the study, but researchers from four other Texas Medical Center institutions are involved: Ming Hu, Ph.D., professor of pharmaceutics at the University of Houston, is helping with the pharmacokinetic analysis; Jagannadha Sastry, Ph.D., Kathryn Shelton, DVM, Ph.D., and Pramod Nehete, Ph.D., with The University of Texas MD Anderson Cancer Center are helping with animal studies; Arduino, from UTHealth, is providing the clinical perspective; and Jason Kimata, Ph.D., associate professor at Baylor College of Medicine, is lending virology expertise.

The project has garnered attention outside of the TMC. Gratton received the 2016 AIDS Foundation Houston Shelby Hodge Vision Award.

And, as director of the Center of Space Nanomedicine at Houston Methodist, Grattoni expects the device to be tested aboard the International Space Station over the next five years.

“We’ve gotten to the point with the research where we have tested the implant to deliver the drug at the preventative level with no adverse effects,” Grattoni said. “We are now working to test our approach on a larger number of subjects and move toward commercial development.”

Tags | Innovation



Social Posts

profile_image

MD Anderson Cancer Center

@MDAndersonNews

.@Myeloma_Doc explains how understanding the biology of #multiplemyeloma will help us unlock new, more effective treatments. #CancerMoonshot #mmsm #endcancer https://t.co/ctkXuu0Y9v

7 mins ago
profile_image

BCMHouston

@bcmhouston

RT @BCMbiotechRusk: BCMBiotech Academy at Rusk students making a difference at the HISD GTExpo. @BCMHouston_News @DDavilaHisd @Drjlarredond…

28 mins ago
profile_image

BCMHouston

@bcmhouston

RT @PeterHotez: Early AM (4-26) start continuing our medical parasitology lectures for 1st yr @bcmhouston medical students in their Micro/I…

29 mins ago
profile_image

Rice University

@RiceUniversity

https://t.co/W9KdUJm5m3

1 hour ago
profile_image

Veterans Affairs

@DeptVetAffairs

#VAntagePoint: Taking part in Prescription Drug Take-Back Day can save lives and protect your loved ones https://t.co/FXG1RQlC1y

2 hours ago

Many have asked how they can support the billboard/flyer media blitz against the pit bull lobbyists. This is exactly how. Donate to the "Pit Bull Truth" Billboard Campaign ASAP if you want to #BanPitBulls and support the #AntiPit campaign against the deceptive Pit Bull Lobby. All of our efforts so far have been a massive success and it's time to kick things up a notch!

2 hours ago
profile_image

MD Anderson Cancer Center

@MDAndersonNews

#DYK that some caffeine sources may reduce your risk for certain cancers? More caffeine perks and pitfalls: https://t.co/y9IVk7lhYH @focusedonhealth #endcancer https://t.co/6agO1Bn9fS

2 hours ago
profile_image

Houston Methodist

@MethodistHosp

@SarahforHD134 Thanks for sharing ^SF

9 hours ago
profile_image

Houston Methodist

@MethodistHosp

@drvrvaidya Thanks for the shout-out ^SF

9 hours ago
profile_image

Houston Methodist

@MethodistHosp

@debby_keller Thanks for sharing ^SF

9 hours ago
profile_image

MD Anderson Cancer Center

@MDAndersonNews

@bigdock Great news! Sending you our best wishes.

11 hours ago

If you love citrus, you will really love these recipes with options from salad to stir-fry.

11 hours ago
profile_image

University of Houston

@UHouston

Legacy is planting seeds in a garden you never get to see. Tonight we’re celebrating the legacy of @UHValentiSchool. Thank you @seguntheprogram for being MC and @jdbalart for the Impact Award https://t.co/tBmWEylyiU

13 hours ago
profile_image

BCMHouston

@bcmhouston

Entering a new era: learn more about TMC3, the new translational research campus. https://t.co/pCLaez3zts

13 hours ago

Be a part of the nation's largest autism research study. Get in-person help with signing up for SPARK for Autism at the Houston Museum of Natural Science during their sensory friendly event April 28. http://bit.ly/SPARKevents

13 hours ago